Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Change in Receivables (2022 - 2025)

Historic Change in Receivables for Rhythm Pharmaceuticals (RYTM) over the last 4 years, with Q3 2025 value amounting to $6.6 million.

  • Rhythm Pharmaceuticals' Change in Receivables rose 28641.69% to $6.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.0 million, marking a year-over-year increase of 17179.43%. This contributed to the annual value of $3.6 million for FY2024, which is 5782.71% down from last year.
  • According to the latest figures from Q3 2025, Rhythm Pharmaceuticals' Change in Receivables is $6.6 million, which was up 28641.69% from $7.8 million recorded in Q2 2025.
  • Rhythm Pharmaceuticals' Change in Receivables' 5-year high stood at $7.8 million during Q2 2025, with a 5-year trough of -$794000.0 in Q4 2024.
  • Over the past 4 years, Rhythm Pharmaceuticals' median Change in Receivables value was $1.7 million (recorded in 2024), while the average stood at $2.3 million.
  • In the last 5 years, Rhythm Pharmaceuticals' Change in Receivables plummeted by 34355.83% in 2024 and then skyrocketed by 28641.69% in 2025.
  • Rhythm Pharmaceuticals' Change in Receivables (Quarter) stood at $2.9 million in 2022, then tumbled by 88.74% to $326000.0 in 2023, then plummeted by 343.56% to -$794000.0 in 2024, then surged by 931.23% to $6.6 million in 2025.
  • Its Change in Receivables was $6.6 million in Q3 2025, compared to $7.8 million in Q2 2025 and -$687000.0 in Q1 2025.